Dr Liptrott has a background in pharmacology, immunology, immunopharmacology and molecular cell biology. His research is aimed at investigating the biological interactions of conventional and nanotechnology-enabled medicines as well as other novel therapeutic strategies such as cellular therapies. This work encompasses assessment of the biocompatibility, immuomodulatory potential and risk of these novel therapeutic strategies. An understanding of these, potential, interactions is vital to preclinical evaluation as well enabling future rational design of nanomaterials and therapies. In addition to immunological and haematological systems, Dr Liptrott's team is also investigating impacts on cellular health and metabolism that may underpin these interactions. Additionally, we are building structure-activity relationships between nanomaterial characteristics and their impact on biological systems using established, as well as novel, techniques.
Dr Liptrott’s research to date has helped underpin the successful translation of solid drug nanoparticle formulations through GMP manufacture towards healthy volunteer bioequivalence studies. Dr Liptrott also worked as a guest researcher at the National Institutes of Health (NIH) National Cancer Institute’s (NCI) Nanotechnology Characterisation Laboratory (NCL) based in Frederick, Maryland, USA. During this time Dr Liptrott conducted research alongside global experts in nanomaterial toxicity and biocompatibility.
In 2015 Dr Liptrott was awarded a tenure-track fellowship within the department of Molecular and Clinical Pharmacology and subseqiently confirmed as a Lecturer in the Department of Molecular and Clinical Pharmacology where he heads the nanotechnology biocompatibility research programmes. Additionally, Dr Liptrott is a member of the Executive Board, Core Expert Team (CET) and Assay Group leader (Immunotoxicity and Haematoxicity) for the recently established European Nanomedicine Characterisation Laboratory (EUNCL), funded by the European Commission. He leads the University of Liverpool work packages on nanoparticle biocompatibility and structure-activity relationships. Dr Liptrott continues to receive numerous national and international invitations to speak as well as being a peer reviewer for a number of scientific journals including those with a focus on nanomedicine.
- Young Investigator Award (CROI Foundation 2013)
- Young Investigator Award (CROI Foundation 2010)
- “Application of Nanotechnology in Drug Delivery" (Invitation to Speak, University of Surrey 2014)
- “Use of in vitro testing for assessing the immunogenicity of nanomaterials” (Invitation to Speak, University of Keele 2014)
- “New Approaches to antiretroviral drug delivery” (Invitation to Speak, CROI Foundation 2013)
- “Application of flow cytometry to nanoparticle characteristics and protein binding" (Invitation to Speak, London Research Institute, Cancer Research UK 2013)
- Pre-doctoral Poster Presentation (International Society for the Study of Xenobiotics (ISSX) 2006)
- Deputy departmental safety coordinator